A study examined whether AI and clinical knowledge can identify more patients with lung and ovarian cancers. The addition of dostarlimab to platinum chemotherapy is cost effective and significantly improves QOL. Dr. Timothy Yap discusses the PETRA trial, which showed the efficacy of saruparib in treating HER2-negative breast cancer. Soft tumor environments can cause triple-negative breast cancer to spread more aggressively. Darwin Kwok discusses how he felt about winning the award and what he’s learned from past recipients. The use of a 3D variable flip angle mapping technique is effective in patients with head and neck cancer undergoing CRT. A blood-based machine learning assay may be able to differentiate patients with ovarian cancer from healthy patients. Patients with a history of venous thromboembolism were more likely to receive VTE prophylaxis. Patients ≥70 years of age were more likely to have a reduction in their palbociclib dosage. Rates of treatment-related hypersensitivity reactions were low in an academic community setting. Same-day administration of pegfilgrastim was not linked to a greater incidence of grade ≥3 neutropenia. Lenvatinib plus pembrolizumab led to a clinically relevant response in patients with baseline metastasis. Higher average talazoparib concentrations were associated with an increased risk of severe anemia and thrombocytopenia. Decreasing the at-home dose of dexamethasone before paclitaxel treatment may help reduce the incidence of infusion reactions. Protected administrative time was ranked as the most important change to improve well-being. Ibrutinib dose reductions were associated with fewer recurrent cardiac adverse events in patients with B-cell malignancies. The REMEDY trial evaluated remote continuous temperature monitoring in patients receiving cytotoxic chemotherapy. Cemiplimab plus chemotherapy as a first-line treatment for advanced NSCLC led to improved survival. Dr. Samilia Obeng-Gyasi discusses how social factors can impact outcomes in breast cancer patients. Ovarian cancer patients value personalized follow-up care and reassurance.